RAS mutation triggers constitutive activation of downstream effectors such as MAPK and PI3K cascades to promote the malignant transformation and progression of CRC and confers resistance to anti-EGFR antibodies [4, 39]. Here, EGFR is linked to colorectal carcinoma.